Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins

In the pharmaceutical industry, improving the early detection of drug-induced hepatotoxicity is essential as it is one of the most important reasons for attrition of candidate drugs during the later stages of drug development. The first objective of this study was to better characterize different cellular models (i.e., HepG2, HepaRG cells, and fresh primary human hepatocytes) at the gene expression level and analyze their metabolic cytochrome P450 capabilities. The cellular models were exposed to three different CYP450 inducers; beta-naphthoflavone (BNF), phenobarbital (PB), and rifampicin (RIF). HepG2 cells responded very weakly to the different inducers at the gene expression level, and this translated generally into low CYP450 activities in the induced cells compared with the control cells. On the contrary, HepaRG cells and the three human donors were inducible after exposure to BNF, PB, and RIF according to gene expression responses and CYP450 activities. Consequently, HepaRG cells could be used in screening as a substitute and/or in complement to primary hepatocytes for CYP induction studies. The second objective was to investigate the predictivity of the different cellular models to detect hepatotoxins (16 hepatotoxic and 5 nonhepatotoxic compounds). Specificity was 100% with the different cellular models tested. Cryopreserved human hepatocytes gave the highest sensitivity, ranging from 31% to 44% (depending on the donor), followed by lower sensitivity (13%) for HepaRG and HepG2 cells (6.3%). Overall, none of the models under study gave desirable sensitivities (80–100%). Consequently, a high metabolic capacity and CYP inducibility in cell lines does not necessarily correlate with a high sensitivity for the detection of hepatotoxic drugs. Further investigations are necessary to compare different cellular models and determine those that are best suited for the detection of hepatotoxic compounds.

[1]  J. G. Kenna,et al.  Cell based approaches for evaluation of drug-induced liver injury. , 2010, Toxicology.

[2]  C. Westmoreland,et al.  Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  Yuichiro Kanno,et al.  A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells. , 2010, The Journal of toxicological sciences.

[4]  Dolores Diaz,et al.  Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. , 2004, Chemico-biological interactions.

[5]  Etienne Hanon,et al.  The Use of Real-Time Cell Analyzer Technology in Drug Discovery: Defining Optimal Cell Culture Conditions and Assay Reproducibility with Different Adherent Cellular Models , 2011, Journal of biomolecular screening.

[6]  D. Lagadic-Gossmann,et al.  Liver Protection from Apoptosis Requires Both Blockage of Initiator Caspase Activities and Inhibition of ASK1/JNK Pathway via Glutathione S-Transferase Regulation* , 2002, The Journal of Biological Chemistry.

[7]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[8]  B. Digregorio,et al.  Biobased performance bioplastic: Mirel. , 2009, Chemistry & biology.

[9]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Geraldine A Hamilton,et al.  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[11]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  C. Guguen-Guillouzo,et al.  Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. , 2011, Toxicology and applied pharmacology.

[13]  A. Parkinson,et al.  Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. , 1996, Archives of biochemistry and biophysics.

[14]  Jörg C Gerlach,et al.  HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.

[15]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[16]  A. Guillouzo,et al.  Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .

[17]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[18]  A. Guillouzo,et al.  Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. , 2009, Toxicology and applied pharmacology.

[19]  Christina Magkoufopoulou,et al.  Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  A. Kong,et al.  Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.

[21]  H. Kanazawa,et al.  Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry. , 2004, Journal of chromatography. A.

[22]  Mark D. Johnson,et al.  Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. , 2004, Biochemical pharmacology.

[23]  M. T. Donato,et al.  Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Goldstein,et al.  The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. , 2004, Molecular pharmacology.

[25]  V. Cohn.  Drug metabolism. , 2020, Advances in biology of skin.

[26]  Stephen C. Harris,et al.  Rat toxicogenomic study reveals analytical consistency across microarray platforms , 2006, Nature Biotechnology.

[27]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[28]  F. Atienzar,et al.  Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[29]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[30]  O. Sugita,et al.  Drug metabolism by the human hepatoma cell, Hep G2. , 1987, Biochemical and biophysical research communications.

[31]  E. Hiyama,et al.  Evaluation of genes identified by microarray analysis in favorable neuroblastoma , 2009, Pediatric Surgery International.

[32]  P. Olinga,et al.  Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Kathy Carroll,et al.  Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes , 2000, Journal of biochemical and molecular toxicology.

[34]  James S MacDonald,et al.  Toxicity testing in the 21st century: a view from the pharmaceutical industry. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  B. Andrews,et al.  New Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models , 2005, Toxicologic pathology.

[36]  Karen Lowrie,et al.  Toxicity testing in the 21st century. , 2009, Risk analysis : an official publication of the Society for Risk Analysis.

[37]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Schoonen,et al.  Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[39]  Guo-Dong Zhou,et al.  Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[41]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[42]  B. Wen,et al.  Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. , 2009, Chemico-biological interactions.

[43]  A. Guillouzo,et al.  Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[44]  J V Castell,et al.  Cell lines: a tool for in vitro drug metabolism studies. , 2008, Current drug metabolism.

[45]  A. Sinskey,et al.  Disparity between changes in mRNA abundance and enzyme activity in Corynebacterium glutamicum:implications for DNA microarray analysis , 2003, Applied Microbiology and Biotechnology.

[46]  N. J. Hewitt,et al.  Phase I and II enzyme characterization of two sources of HepG2 cell lines , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[48]  R. Franklin,et al.  Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2. , 2011, Journal of pharmacological and toxicological methods.

[49]  W. Schoonen,et al.  Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[50]  S. Feinstein,et al.  Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. , 2009, Chemistry & biology.